BeyondSpring closed at $0.62 on Nov 3, down 22.94%, 73.6% below its 52-week closing high. Volume of 236.2K shares was 1.82× its 20-day average (above normal).
Split-adjusted performance: -21.0% over one month, -56.9% over six months, -68.8% over one year.
Short interest was 2.4M shares at the Oct 15 settlement, down 3.7% from the prior report (7.5% of float, 35.8 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −26.5%, revenue growth +6.4%, net margin −38.1%, P/E 16.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| BYSIBeyondSpring | $0.6210 | −22.94% | −56.9% | — | — | — | $25.5M | |
| CPHIChina Pharma Holdings | $0.6092 | +0.48% | +10.3% | −7.5% | −153.8% | — | $26.2M | Compare |
| BCTXBriacell Therapeutics | $3.01 | −2.59% | −26.0% | — | — | — | $26.3M | Compare |
| ABVCABVC BioPharma | $0.9851 | +0.51% | −4.4% | — | — | — | $26.3M | Compare |
| CELUCelularity | $0.8171 | +1.82% | −14.3% | −5.3% | 10.1% | — | $26.5M | Compare |
| SHPHShuttle Pharmaceuticals Holdings | $5.15 | +4.04% | −34.7% | — | — | — | $24.5M | Compare |
| RNAZTransCode Therapeutics | $1.57 | −3.68% | −80.0% | — | — | — | $26.6M | Compare |
| AARDAardvark Therapeutics | $1.23 | +2.50% | −77.5% | — | — | — | $26.9M | Compare |
| NXTCNextCure | $5.91 | +3.78% | −36.6% | — | — | — | $27.1M | Compare |
No recent articles focused on BeyondSpring.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
